By Drug Class / Mechanism

Monoclonal Antibodies & Antibody Fragments (Anti-IGF-1R, Anti-IL-6R) Market Analysis

Cross-industry research covering Monoclonal Antibodies & Antibody Fragments (Anti-IGF-1R, Anti-IL-6R) across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports

1 Industries

Reports Covering Monoclonal Antibodies & Antibody Fragments (Anti-IGF-1R, Anti-IL-6R)

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

The fastest-growing drug-class segment, anchored by anti-IGF-1R biologics in TED. VRDN-003's Phase 3 program across three concurrent trials (NCT06625411, NCT06625398, NCT07155668) is the most active NDA-track asset; BLA submission is anticipated in 2026–2027 if all three trials read out positively (Claritas model).

24%

Market Share

16.4%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments